603707.SS SHH
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
1W: +3.1%
1M: +3.1%
3M: +9.8%
YTD: -18.4%
1Y: -28.4%
3Y: -37.5%
5Y: -66.3%
¥8.19 ($1.22)
+0.30 (+3.80%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$1.5B
-7.3% ▼
Capital Expenditures
$507M
-20.9% ▼
5Y CAGR: +34.4%
Free Cash Flow
$994M
-17.1% ▼
Dividends Paid
$213M
+14.2% ▲
Buybacks
$12M
-110.5% ▼
Net Change in Cash
-$157M
-126.6% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $797M | $1.1B | $1.1B | -$189M | $826M |
| Depreciation & Amort. | $85M | $93M | $140M | $154M | $175M |
| Stock-Based Comp. | $8M | $9M | $28M | $43M | $0 |
| Change in Working Capital | -$1.6B | -$557M | -$506M | $355M | $400M |
| Other Non-Cash Items | $119M | $86M | -$123M | $1.3B | $101M |
| Operating Cash Flow | -$566M | $684M | $595M | $1.6B | $1.5B |
| — Investing Activities — | |||||
| Capital Expenditures | -$294M | -$441M | -$470M | -$419M | -$507M |
| Acquisitions (Net) | $117K | -$14M | $112K | $0 | $0 |
| Investment Purchases | -$2.6B | -$3.1B | -$2.0B | -$2.3B | -$3.6B |
| Investment Sales | $1.7B | $3.8B | $2.1B | $1.6B | $3.2B |
| Other Investing | $1M | $540K | $0 | $153K | $2K |
| Investing Cash Flow | -$1.2B | $170M | -$400M | -$1.2B | -$911M |
| — Financing Activities — | |||||
| Net Debt Issuance | $762M | -$560M | -$81M | $308M | -$503M |
| Stock Repurchased | -$1M | -$874K | -$1M | -$6M | -$12M |
| Dividends Paid | -$216M | -$140M | -$187M | -$248M | -$213M |
| Other Financing | $1.5B | -$160M | -$43M | -$3M | -$3M |
| Financing Cash Flow | $2.0B | -$912M | -$311M | $51M | -$731M |
| Net Change in Cash | $225M | -$39M | -$132M | $592M | -$157M |
| Cash End of Period | $473M | $435M | $303M | $894M | $737M |
| Free Cash Flow | -$860M | $243M | $125M | $1.2B | $994M |